<DOC>
	<DOCNO>NCT01073384</DOCNO>
	<brief_summary>The purpose study evaluate safety preliminary efficacy four dos SGX201 subject rectal cancer treat concurrent radiation chemotherapy .</brief_summary>
	<brief_title>A Dose Ranging Study Delayed Release Beclomethasone Prevention Acute Enteritis Patients With Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Primary rectal cancer Planned course conventional neoadjuvant radiation therapy surgery Scheduled receive chemotherapy &gt; /= 18 year age Negative pregnancy test History acute chronic regional enteritis inflammatory bowel disease Stool incontinence Uncontrollable diarrhea Abdominalperineal resection surgery leave patient without function rectum Patients use colostomy ileostomy Liver function test &gt; 3x upper limit normal , bilirubin test result &gt; 1.5 upper limit normal Calculated creatinine clearance &lt; 60 mL/minute Planned hyperfractionated split course radiation Planned brachytherapy prior completion external beam radiation therapy Prior pelvic RT An ongoing infection ECOG score &gt; /= 3 Leukopenia &lt; 2,000 WBC/mm3 Hg &lt; 10.5 g/dL Participation investigational drug trial within previous 30 day Patients medical condition would interfere study compliance Known hypersensitivity 5FU capecitabine Anticipated inability tolerate oral administration SGX201 Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>